FDA and EMA grant orphan designations to FLAG-003 for glioma

FDA and the European Medicines Agency have both granted Orphan Drug Designation to FLAG-003 for the treatment of glioma, sponsored by FLAG Therapeutics. Orphan status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases, those which affect fewer than 200,000 Americans annually. Orphan drug...